Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells
Increasing evidence shows that targeting epigenetic changes including acetylation and deacetylation of core nucleosomal histones as well as Aurora kinases hold promise for improving the treatment of human cancers including ovarian cancer. We investigated whether the histone deacetylase (HDAC) inhibi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2013-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fonc.2013.00058/full |
| _version_ | 1818649611670126592 |
|---|---|
| author | Yanfang Li Tao Liu Cristina Ivan Cristina Ivan Jie Huang De-Yu Shen John J. Kavanagh Robert C. Bast Siqing Fu Wei Hu Anil K. Sood Anil K. Sood Anil K. Sood |
| author_facet | Yanfang Li Tao Liu Cristina Ivan Cristina Ivan Jie Huang De-Yu Shen John J. Kavanagh Robert C. Bast Siqing Fu Wei Hu Anil K. Sood Anil K. Sood Anil K. Sood |
| author_sort | Yanfang Li |
| collection | DOAJ |
| description | Increasing evidence shows that targeting epigenetic changes including acetylation and deacetylation of core nucleosomal histones as well as Aurora kinases hold promise for improving the treatment of human cancers including ovarian cancer. We investigated whether the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), and the Aurora kinase inhibitor VE465 can have additive or synergistic effects on gynecologic cancer cells. We tested the in vitro antitumor activity of VPA and VE465, alone and in combination, in gynecologic cancer cells and assessed potential mechanisms of action. 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) analysis revealed that 72 h of treatment with VPA or VE465 alone induced dose-dependent cytotoxic effects in nine gynecologic cancer cell lines (ovarian: 2008/C13, OVCAR3, SKOV3, and A2780; cervical: ME180 and CaSki; endometrial: HEC-1B; and uterine sarcoma: MES-SA and MES-SA/D×5). Co-treatment with VPA and VE465 enhanced cytotoxic effects on five of these cell lines: ovarian: 2008/C13, A2780, and OVCAR3; endometrial: HEC-1B; and cervical: ME180. In ovarian 2008/C13 cells, co-treatment with VPA (2 mM) and VE465 (1 μM) induced more apoptosis than either VPA or VE465 alone. Western blot analysis showed that VPA alone increased the expression of cleaved PARP and p21 in a dose-dependent manner in 2008/C13 cells, while co-treatment with VPA and VE465 induced more cleaved PARP than treatment with VPA or VE465 alone did. The combined use of VPA and VE465 enhanced cytotoxic effects in some ovarian cancer cells, via enhanced induction of apoptosis. Targeting epigenetics with the HDAC inhibitor, in combination with Aurora kinase inhibitors, holds promise for more effective therapy of ovarian cancer. |
| first_indexed | 2024-12-17T01:37:05Z |
| format | Article |
| id | doaj.art-f5dd9bcfb6804d7dbd66a9594be8f1a9 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-17T01:37:05Z |
| publishDate | 2013-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f5dd9bcfb6804d7dbd66a9594be8f1a92022-12-21T22:08:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2013-03-01310.3389/fonc.2013.0005841997Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer CellsYanfang Li0Tao Liu1Cristina Ivan2Cristina Ivan3Jie Huang4De-Yu Shen5John J. Kavanagh6Robert C. Bast7Siqing Fu8Wei Hu9Anil K. Sood10Anil K. Sood11Anil K. Sood12Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHouston, TX, USACenter for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Experimental Therapeutics, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Investigative Cancer Therapeutics, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHouston, TX, USACenter for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer CenterHouston, TX, USADepartments of Cancer Biology, The University of Texas MD Anderson Cancer CenterHouston, TX, USAIncreasing evidence shows that targeting epigenetic changes including acetylation and deacetylation of core nucleosomal histones as well as Aurora kinases hold promise for improving the treatment of human cancers including ovarian cancer. We investigated whether the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), and the Aurora kinase inhibitor VE465 can have additive or synergistic effects on gynecologic cancer cells. We tested the in vitro antitumor activity of VPA and VE465, alone and in combination, in gynecologic cancer cells and assessed potential mechanisms of action. 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) analysis revealed that 72 h of treatment with VPA or VE465 alone induced dose-dependent cytotoxic effects in nine gynecologic cancer cell lines (ovarian: 2008/C13, OVCAR3, SKOV3, and A2780; cervical: ME180 and CaSki; endometrial: HEC-1B; and uterine sarcoma: MES-SA and MES-SA/D×5). Co-treatment with VPA and VE465 enhanced cytotoxic effects on five of these cell lines: ovarian: 2008/C13, A2780, and OVCAR3; endometrial: HEC-1B; and cervical: ME180. In ovarian 2008/C13 cells, co-treatment with VPA (2 mM) and VE465 (1 μM) induced more apoptosis than either VPA or VE465 alone. Western blot analysis showed that VPA alone increased the expression of cleaved PARP and p21 in a dose-dependent manner in 2008/C13 cells, while co-treatment with VPA and VE465 induced more cleaved PARP than treatment with VPA or VE465 alone did. The combined use of VPA and VE465 enhanced cytotoxic effects in some ovarian cancer cells, via enhanced induction of apoptosis. Targeting epigenetics with the HDAC inhibitor, in combination with Aurora kinase inhibitors, holds promise for more effective therapy of ovarian cancer.http://journal.frontiersin.org/article/10.3389/fonc.2013.00058/fullvalproic acidAurora kinase inhibitorovarian cancercervical cancerendometrial cancer |
| spellingShingle | Yanfang Li Tao Liu Cristina Ivan Cristina Ivan Jie Huang De-Yu Shen John J. Kavanagh Robert C. Bast Siqing Fu Wei Hu Anil K. Sood Anil K. Sood Anil K. Sood Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells Frontiers in Oncology valproic acid Aurora kinase inhibitor ovarian cancer cervical cancer endometrial cancer |
| title | Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells |
| title_full | Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells |
| title_fullStr | Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells |
| title_full_unstemmed | Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells |
| title_short | Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells |
| title_sort | enhanced cytotoxic effects of combined valproic acid and the aurora kinase inhibitor ve465 on gynecologic cancer cells |
| topic | valproic acid Aurora kinase inhibitor ovarian cancer cervical cancer endometrial cancer |
| url | http://journal.frontiersin.org/article/10.3389/fonc.2013.00058/full |
| work_keys_str_mv | AT yanfangli enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT taoliu enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT cristinaivan enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT cristinaivan enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT jiehuang enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT deyushen enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT johnjkavanagh enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT robertcbast enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT siqingfu enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT weihu enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT anilksood enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT anilksood enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells AT anilksood enhancedcytotoxiceffectsofcombinedvalproicacidandtheaurorakinaseinhibitorve465ongynecologiccancercells |